Background-Atherosclerosis, the precursor to coronary heart disease and stroke, is characterized by an accumulation of fatty cells in the arterial intimal-medial layers. Common carotid intima media thickness (cIMT) and plaque are subclinical atherosclerosis measures that predict cardiovascular disease events. Previously, genome-wide association studies demonstrated evidence for association with cIMT (SLC17A4) and plaque (PIK3CG). Methods and Results-We sequenced 120 kb around SLC17A4 (6p22.2) and 251 kb around PIK3CG (7q22.3) among 3669 European ancestry participants from the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study (CHS), and Framingham Heart Study (FHS) in Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Primary analyses focused on 438 common variants (minor allele frequency ≥1%), which were independently meta-analyzed. A 3ʹ untranslated region CCDC71L variant (rs2286149), upstream from PIK3CG, was the most significant finding in cIMT (P=0.00033) and plaque (P=0.0004) analyses. A SLC17A4 intronic variant was also associated with cIMT (P=0.008). Both were in low linkage disequilibrium with the genome-wide association study single nucleotide polymorphisms. Gene-based tests including T1 count and sequence kernel association test for rare variants (minor allele frequency <1%) did not yield statistically significant associations. However, we observed nominal associations for rare variants in CCDC71L and SLC17A3 with cIMT and of the entire 7q22 region with plaque (P=0.05). Conclusions-Common and rare variants in PIK3CG and SLC17A4 regions demonstrated modest association with subclinical atherosclerosis traits. Although not conclusive, these findings may help to understand the genetic architecture of regions previously implicated by genome-wide association studies and identify variants within these regions for further investigation in larger samples. (Circ Cardiovasc Genet. 2014;7:359-364.)
A therosclerosis, a precursor to clinical coronary artery disease and some strokes, is characterized by an accumulation of fatty and inflammatory cells and fibrosis in the intimal-medial layers of the arteries. Common carotid intima media thickness (cIMT) and plaque, reflecting a thickening of the carotid artery wall or the presence of large irregular arterial wall deposits, respectively, are established measures of subclinical atherosclerotic disease that can be detected noninvasively and with reasonable precision in population samples using high-resolution ultrasound techniques. Multiple independent studies have established consistent association of abnormal carotid phenotypes with coronary events and stroke in prospective studies of young, middle-aged, and older adults, 1,2 and recent consensus prevention guidelines cite cIMT as a potentially useful measure for the prediction of these outcomes. 3 We have previously identified 2 regions that demonstrated evidence for association with cIMT (SLC17A4) and carotid plaque (PIK3CG) in a large-scale genome-wide association meta-analysis conducted among >40 000 participants from population-based studies of European ancestry adults. 4 Recent studies have shown that targeted genome sequencing can identify a significant excess burden of functional variants underlying genome-wide association study (GWAS) signals. 5 To identify the causal variants accounting for these signals, we performed a targeted sequencing of these loci using next-generation technology. The first region is a 120 kb window on chromosome 6p22.2 including the SLC17A4, SLC17A1, and SLC17A3 genes that showed suggestive evidence for association with common cIMT in the GWAS (rs4712972; minor allele frequency [MAF], 0.12; β=0.0099; P=7.8×10 −8 ). 4 The second targeted region is a 251 kb stretch of chromosome 7q22. 3 including the PIK3CG gene that was significantly associated with increased risk of carotid plaque in the GWAS (rs17398575; MAF, 0.25; odds ratio, 1.18; P=2×10 −12 ). 4 In addition to the association with plaque, this region was also selected for sequencing on the basis of its association in recent GWAS with both platelet volume 6 and aggregation 7 as well as pulse pressure. 8 Rather than identifying new susceptibility loci, our aim was to better characterize the landscape of common and rare variation in these previously associated regions and to determine whether novel or low-frequency variation therein was associated with cIMT and carotid plaque. Such fine-mapping across the full spectrum of allele frequencies may help to explain the previous genome-wide associations and provide new information on the potential mechanisms of atherosclerosis that could contribute to subclinical cardiovascular disease.
Methods

Participating Studies
Our analyses were performed within Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study, which included 3688 European ancestry participants from the Atherosclerosis Risk in Communities (ARIC) study, 10 the Cardiovascular Health Study 11 (CHS), and the Framingham Heart Study 12, 13 (FHS) . This sample included a sex-stratified subset of ≈200 individuals who were selected for elevated measures of age-adjusted cIMT (see Data Supplement). The remainder of the participants in this study was selected as part of a large random sample or for extreme values of 13 other cardiovascular-related phenotypes. Institutional review boards at all participating centers approved the study, and participants gave informed consent. Additional information about the design of these studies is included in the Data Supplement.
Carotid Artery Phenotypes
Each study evaluated the carotid arteries using high-resolution B-mode ultrasonography, using previously described reading protocols to define phenotypes, as per our previous report. 4 For these analyses, we used data from the baseline examination or the first examination in which carotid ultrasonography was obtained. Our primary analysis concerned the common carotid artery using the intima media thickness, typically summarized as the mean of the maximum of several carotid measurements. For most studies, this was an average of multiple measurements from both left and right arteries. All studies measured the far wall, and several also included the near wall. We also examined the atherosclerotic thickening of the carotid artery wall, defined in 2 studies by the presence of plaque (CHS, ARIC) or the proxy measure of luminal stenosis >25% (FHS). Specific details for each study's ultrasound, reading, and plaque definition protocols are provided in the Data Supplement.
Sequencing
The methods of the CHARGE Targeted Sequencing Study are described in a separate article. 14 Briefly, the study sequenced a total of 77 target regions that harbor genetic variants associated with 14 phenotypes implicated by GWAS within CHARGE Consortium. Two of the selected genes were particularly relevant to subclinical atherosclerosis. First, the Subclinical Phenotype Group used the University of California at Santa Cruz Genome Browser to select target sequence upstream and downstream of the SLC17A4/3/1 genes. Second, the Pleiotropy Phenotype Group selected the PIK3CG region with the aim of capturing both the gene and the upstream CCDC71L gene and other untranslated regions that harbored single nucleotide polymorphisms (SNPs) identified in several GWAS.
Approximately 2 Mb of target regions was captured by a customized NimbleGen Capture array and sequenced using the ABI SOLiD V4.0 platform. The raw short reads were aligned to the reference human genome (NCBI Genome Build 36; hg18) by BFAST. 15 SAMtools 16 was used to pile up aligned reads and call variants with quality filters. The resulting data were then subjected to quality control procedures. Variants were categorized as known or novel by comparison with the dbSNP database and the 1000 Genomes Project. The functional impact of identified variants on the encoded proteins was predicted by the ANNOVAR software package. 17
Statistical Analysis Within Studies
Each study independently implemented a predefined and standardized analysis plan, as described below.
For the continuous measures of cIMT, we evaluated cross-sectional associations of natural log of cIMT (ln[cIMT]) and genetic variation using linear regression models (or linear mixed-effects models in FHS to account for family relatedness). For the dichotomous outcome of plaque, each study used logistic regression models (or general estimating equations clustering on family, to account for familial correlations). In our primary analyses, all studies were adjusted for age, sex, and principal components to account for population substructure (as needed). Some studies made additional adjustments including study site (CHS, ARIC) or familial structure (FHS). For cIMT, we expressed the association of each SNP and ln(cIMT) as the regression slope (β), its standard error (SE[β]), and a corresponding P value. For the presence of plaque, we calculated a log odds ratio, 95% confidence interval, and P value. In this case, the odds ratio represents the increase or decrease in the odds of plaque for each additional copy of the variant's coded allele. Each study repeated these analyses weighted by each participant's sampling probability to obtain valid estimates of effect size (Lumley T et al, unpublished data; http://stattech.wordpress.fos.auckland.ac.nz/files/2012/05/design-paper.pdf).
We applied 2 methods of analysis within each region for each of these traits. For each variant with a MAF ≥1% in the combined population, each study fit additive genetic models, regressing trait on genotype dosage (0-2 copies of the variant allele). For rare variants, our primary analyses aggregated rare alleles, that is, those with MAF <1% into a T1 count statistic, which was defined as the number of variant sites in the target at which a person has ≥1 rare allele with MAF <1%. In secondary rare variant analyses of our target regions, we used 2 approaches. (1) First, we used a Madsen-Browning type test, which aggregates all variants with MAF<1% in a genomic region, weighting each variant by a function of its MAF. 18 (2) Second, to explore the possibility that rare variants within a gene did not have the same direction or magnitude of association, we implemented the sequence kernel association test, 19 which approximates the score test that would be obtained fitting a model that includes all the variants. 20 We then conducted a meta-analysis of regression estimates and standard errors using an inverse-variance weighting approach, implemented in METAL 21 or, for sequence kernel association test, using customized R scripts (Lumley T et al, unpublished data; http://stattech.wordpress.fos.auckland.ac.nz/files/2012/11/skat-meta-paper. pdf). For the meta-analysis of common variants, we excluded SNPs observed in only 1 study and discarded results with heterogeneity P values <1×10 -5 . As described above, meta-analysis of unweighted regression coefficients was used to determine significance, and meta-analysis of weighted regression coefficients was used to estimate effect size for single variants.
Our primary hypotheses focused on the descriptive analyses of genetic sequence variants in the SLC17A4 and PIK3CG regions. Given the previous evidence for these 2 regions, we used a P value threshold of <0.01 to identify common variants of potential interest. However, we also performed exploratory analyses across the remaining 75 sequenced targets. Given the hypothesis-free nature of these analyses, we considered only regions satisfying a more stringent target-wide significance threshold (P<1×10 -5 for common SNPs: 0.05/4800 common variants across the entire sequencing project; or P<0.00067: 0.05/75 targets for burden tests).
Regulatory Function of SNPs
We used HaploReg 22 to evaluate regulatory function for variants identified in the study (http://www.broadinstitute.org/mammals/haploreg/haploreg.php). HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks that uses linkage disequilibrium (LD) information from the 1000 Genomes Project. Linked SNPs and small indels are visualized for conservation across mammals, their effect on regulatory motifs from the Encyclopedia of DNA Elements Consortium, and their predicted chromatin state in 9 cell types: embryonic stem cells (H1 ES), erythrocytic leukemia cells (K562), B-lymphoblastoid cells (GM12878), hepatocellular carcinoma cells (HepG2), human umbilical vein endothelial cells (Huvec), skeletal muscle myoblasts, normal lung fibroblasts, normal epidermal keratinocytes, and mammary epithelial cells.
Results
Our analysis included 3669 participants who had carotid ultrasound measures and successful targeted sequencing. Characteristics of these participants are shown in Table 1 according to whether they were sampled into the study for extreme values of cIMT, extreme values of another cardiovascular phenotype, or as part of the cohort random sample. As expected, participants sampled from the cIMT extremes had greater cIMT and were more likely to have plaque, whereas those sampled for other cardiovascular traits resembled the cohort random sample in terms of these subclinical atherosclerosis phenotypes.
The overall CHARGE Targeted Sequencing Study identified 52 736 variants across all successfully sequenced participants; most were rare variants (only 4800 had a MAF >1%). Our primary analyses focused on 3767 variants in 2 genomic regions, 6p22 (110 common, 656 rare) and 7q22 (328 common, 2673 rare), that had been previously associated with subclinical atherosclerosis traits. A summary of the genomic annotation for these variants is shown in Table I in the Data Supplement.
Common Variants Results
The Figure displays the regional plots with results of the meta-analysis for common variants in the 6p22 and 7q22 regions; Tables IIA and IIB in the Data Supplement present the results for individual common variants with P<0.01 for either cIMT or plaque. Figure IA and IB in the Data Supplement shows the Manhattan plot of all common variant associations across the 77 target regions for cIMT and plaque.
For the 6p22 region spanning SLC17A4, the strongest finding was for a newly discovered intronic variant with cIMT (rs141877104; MAF, 0.015; P=0.008). This variant was in low LD (r 2 =0.003) with the common GWAS signal SNP (rs4712972), which was only nominally associated with cIMT in our sequenced subsample (P=0.04). In the analysis of plaque, another intronic SLC17A4 variant (rs76788698; MAF, 0.021) was modestly associated with the presence of plaque (P=0.04) and was in low LD with rs4712972 (r 2 =0.1). Although the correlation-based estimates of LD for these SNPs and the GWAS signal variant were low, there is little evidence of recombination in this region (Dʹ>0.9; Figure) suggesting that the signal GWAS SNP could be tagging underlying rarer variant associations. Although neither of these variants was present in the Phase II HapMap CEU panel, they have been reported in the latest version of the 1000 Genomes Project data.
In the chromosome 7q22 region, we observed the smallest P value for a common variant rs2286149 (MAF, 0.12) for both cIMT (β=0.018; P=0.0003) and plaque (odds ratio, 1.4; P=0.0003). This variant falls in the 3ʹ untranslated region (UTR) of CCDC71L, upstream from the targeted PIK3CG gene. The plaque GWAS signal variant (rs17398575) is located between these 2 genes, but was not significantly associated with the presence of plaque (P=0.5) in this subset sample of the large GWAS and is in low LD (r 2 =0.002; Dʹ=0.11) with rs2286149 in our sequenced sample.
Functional Follow-Up of the Common Variants
Applying HaploReg, we evaluated the regulatory function for variants shown in Table IIA in the Data Supplement. We found that rs2190093 affects the HP1 site factor motif, which is necessary to generate a liver-specific promoter, and is in perfect LD with rs2286149, itself strongly associated with both cIMT (P=0.0007) and plaque (P=0.0004) in this sequencing study. This common variant is located in the 3ʹ UTR region of gene CCDC71L, upstream from the targeted PIK3CG gene. The implicated promoter binds to a liver-specific transcription factor, hepatocyte nuclear factor 1 (HNF1A), which is also known as HNF1 and HNF-1α. HNF1A is known to regulate the expression of several liver-specific genes. On querying TRANSFAC (http://www. biobase-international.com/product/transcription-factor-bindingsites), a unique knowledge base of published data on eukaryotic transcription factors, their experimentally proven binding sites, and regulated genes, we found that the target genes of HNF1A include those related to coagulation, lipids, C-reactive protein, inflammation, and toxic stress ( Table III in the Data Supplement).
Rare Variants
We conducted gene-based rare variant analyses for each of the 2 chromosomal regions as well as for the 5 subregions within these loci defined by the University of California at Santa Cruz gene boundaries ( Table 2 ). We did not observe any statistically significant findings for association between cIMT or plaque with any of these gene-based tests, although we noted suggestive associations of the SLC17A3 subregion with cIMT (Madsen-Browning P=0.04), the CCDC71L subregion with cIMT (T1 P=0.05; sequence kernel association test P=0.05), and the overall 7q22 region with plaque (T1 P=0.05). Furthermore, limiting the sequence kernel association test to a set of potentially functional variants (nonsynonymous, splice sites, or noncoding SNPs with some evidence of regulatory function defined by RegulomeDB.org score <6) with MAF <0.05 did not improve the evidence for association for these genes.
For the remaining 75 regions identified by the CHARGE Targeted Sequencing Study, no common variants or T1 rare variant burdens showed statistically significant associations between cIMT and plaque.
Discussion
In the meta-analysis of association between common sequence variants and subclinical atherosclerosis traits, a variant in the 3ʹ UTR of CCDC71L, rs2286149, showed the smallest P value in both analyses of cIMT and plaque (P=0.0003). This variant is located upstream of the targeted PIK3CG gene. For the 6p22 region, the strongest finding was for an intronic SLC17A4 variant (rs141877104) with cIMT (P=0.008), which provides modest evidence toward localizing the broad GWAS peak to 1 member of the 3-gene cluster. The 7q22 region targeted for sequencing in this study contains 2 genes, PIK3CG and CCDC71L. In addition to the association with plaque in our previous GWAS, variants in this region are also strongly associated with mean platelet volume. 23, 24 In particular, variants in the CCDC71L have been previously associated with the expression of the PIK3CG gene as a platelet expression quantitative trait locus. 6 PIK3CG encodes 1 of the pi3/pi4-kinase family of proteins, important modulators of extracellular signals, including those elicited by E-cadherin-mediated cell-cell adhesion, which plays an important role of endothelin in the maintenance of structural and functional integrity of epithelia. In our sequencing study, a common variant in CCDC71L was strongly associated with both cIMT and plaque. This variant, rs2286149, shows only modest evidence of regulatory function as it alters the Zfp105 regulatory motifs; is an active promoter in several cell types (HMEC, Huvec, K562, and NHLF), is in the polycombrepressed chromatin state in HepG2, and falls within a DNAseI hypersensitivity peak in hepatocytes. In the 3ʹ UTR region of gene CCDC71L, another common variant, rs2190093, is in perfect LD with the top associated SNP rs2286149 (r 2 =1.0) and is also found to be strongly associated with both cIMT and plaque in this sequencing study. rs2190093 affects the binding site of a liver-specific transcription factor, HNF1A. Reported targets of HNF1A include CRP, APOB, APOA2, and coagulation factors including F2, F8, and β-fibrinogen. 25, 26 ITGA2B, platelet glycoprotein IIb, is also a target of HNF1A. Although rs2190093 is in 3ʹ UTR of CCDC71L, it is also located in 5ʹ upstream regulatory region of PIK3CG, which harbors variants associated with both carotid phenotypes as well as platelet number, volume, 23 and aggregation 7 in large GWAS. These results generate the hypothesis that PIK3CG may be an HNF1A target expressed in platelets. Rare variant tests in the CCDC71L gene showed borderline evidence for association with cIMT, and rare variant tests across the entire 7q22 region showed borderline association with plaque.
The chromosome 6p22 region, targeted in this study on the basis of a suggestive association of rs4712972 with common cIMT in our previous GWAS, includes SLC17A4, SLC17A1, and SLC17A3; the products of these genes are involved in renal phosphate homeostasis. Serum phosphate has been associated with subclinical atherosclerosis. 27, 28 SLC17A1 is located in the proximal tubules in the kidney and is responsible for renal excretion of phosphate; SLC17A4 is located in the intestine. In addition, 2 GWAS have associated this region with uric acid levels (SLC17A1, 29 SLC17A3). 30 The association peak was broad in our GWAS that used imputation to the phase II HapMap CEU reference panel, and the strongest associations in this sequenced subset were for intronic variants in the SLC17A4 gene that were not present in the HapMap. There is little evidence for regulatory potential for these 2 variants, though 1 (rs112544908), which modifies a Pax-3 binding site, was associated with cIMT (P=0.009) and modestly with higher risk of plaque (P=0.09).
The GWAS that originally identified these loci as associated with subclinical atherosclerosis traits included a much larger sample and relied on imputation to the Phase II HapMap reference panel. In the current Targeted Sequencing Study, conducted among a subset of participants from 3 cohorts that comprised the large-scale discovery effort, neither of the previous GWAS top SNPs that identified these loci as targets was strongly associated with either of the subclinical traits. This effort was primarily a comprehensive, descriptive analysis targeted to better characterize the variation in regions identified by GWAS; as such, we reported results for variants with P<0.01. However, we acknowledge that few of the findings we described would satisfy a conservative Bonferroni correction for the total number of tests (P=0.0001; 0.05/≈450 common variants) or for 1 expected false-positive accounting for the correlation between the variants (P=0.007; 1/≈140 effectively independent tests). In part, this lack of association could reflect diminished power, particularly for the dichotomous analyses, of this smaller sample size. For instance, our power in the targeted sequencing analysis to discover common variants was excellent (99%) for a single SNP that explained 1% of the overall variance in the trait, but was only moderate (69%) for a variant that explained 0.5% of trait variance. Nevertheless, these findings from fine-mapping may better localize associations. For instance, the original GWAS signal for plaque fell in an apparent recombination region between PIK3CG and CCDC71L. The sequencing data showed no evidence for association of this GWAS variant with plaque, instead exposing CCDC71L, as the potentially relevant locus.
In summary, sequencing of PIK3CG and SLC17A4 regions within a limited number of participants from 3 CHARGE cohorts demonstrated evidence of association between plaque and the PIK3CG region for both common and rare variants. Although not conclusive, these findings may help to better understand the genetic architecture of 2 regions previously implicated in subclinical atherosclerosis.
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